Level Bio (LEVBIO) Q1 2025 earnings summary

Executive summary

• Revenue increased by 42% year-over-year to 7,808 KSEK for Q1 2025, with improved net results and a shift to positive cash flow.

• Achieved 44% year-over-year growth in the Nordic markets, supported by rebranding initiatives.

• Strategic transformation, innovation, and rebranding are driving sales growth and operational improvements.

• Over 50% of targets reached, with significant progress in technology and cost management.

• Distribution subsidiary Techtum Lab secured significant orders and expanded its product portfolio and Nordic presence.

Financial highlights

• Net sales: 7,808 KSEK (5,504 KSEK in Q1 2024), up 42% year-over-year.

• Gross margin: 50% (52% in Q1 2024).

• Operating income: -895 KSEK (-2,525 KSEK in Q1 2024).

• Net income: -836 KSEK (-2,455 KSEK in Q1 2024); EPS: -0.01 SEK (-0.04 SEK in Q1 2024).

• Cash flow: 266 KSEK (-209 KSEK in Q1 2024); cash at period end: 1,345 KSEK.

Outlook and guidance

• Management expects continued growth in 2025, supported by investments in technology, personnel, and market presence.

• Focus remains on expanding Nordic distribution and leveraging a scalable, efficient organizational structure.